Crinetics Pharmaceuticals (CRNX) Competitors $36.50 +1.32 (+3.76%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. RDY, ASND, VTRS, QGEN, BBIO, ROIV, ELAN, VRNA, MRNA, and RVMDShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Moderna (MRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Its Competitors Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris QIAGEN BridgeBio Pharma Roivant Sciences Elanco Animal Health Verona Pharma PLC American Depositary Share Moderna Revolution Medicines Crinetics Pharmaceuticals (NASDAQ:CRNX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Is CRNX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -32.28% -29.45% Dr. Reddy's Laboratories 16.99%17.25%11.63% Which has more risk and volatility, CRNX or RDY? Crinetics Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Which has better earnings and valuation, CRNX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.39M2,469.62-$298.41M-$4.11-8.88Dr. Reddy's Laboratories$3.81B3.10$663M$0.6621.43 Does the media favor CRNX or RDY? In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 2 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.22 beat Crinetics Pharmaceuticals' score of 0.14 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in CRNX or RDY? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend CRNX or RDY? Crinetics Pharmaceuticals presently has a consensus price target of $63.43, indicating a potential upside of 73.76%. Dr. Reddy's Laboratories has a consensus price target of $16.95, indicating a potential upside of 19.83%. Given Crinetics Pharmaceuticals' higher possible upside, equities analysts plainly believe Crinetics Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 SummaryDr. Reddy's Laboratories beats Crinetics Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.44B$2.51B$5.65B$10.26BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-8.8823.2775.7026.05Price / Sales2,469.62571.43514.05168.79Price / CashN/A174.1537.5661.52Price / Book2.555.1512.876.29Net Income-$298.41M$32.95M$3.29B$270.94M7 Day Performance2.88%0.17%-0.33%-0.30%1 Month Performance21.31%5.12%3.77%6.20%1 Year Performance-27.65%1.29%68.18%28.32% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.6383 of 5 stars$36.50+3.8%$63.43+73.8%-29.4%$3.44B$1.39M-8.88210Analyst ForecastRDYDr. Reddy's Laboratories2.8902 of 5 stars$14.64-0.2%$16.95+15.8%-9.3%$12.24B$3.81B22.1727,811Positive NewsASNDAscendis Pharma A/S2.8492 of 5 stars$194.62-0.5%$244.36+25.6%+33.4%$11.97B$393.54M-37.721,017VTRSViatris2.0044 of 5 stars$9.60-3.6%$10.40+8.3%-15.2%$11.61B$14.74B-3.3132,000News CoveragePositive NewsHigh Trading VolumeQGENQIAGEN4.3146 of 5 stars$45.39+0.2%$49.69+9.5%+3.2%$10.07B$1.98B26.825,765BBIOBridgeBio Pharma4.541 of 5 stars$51.47+0.5%$63.94+24.2%+103.7%$9.79B$221.90M-12.58400Positive NewsROIVRoivant Sciences3.2819 of 5 stars$13.95-0.9%$17.67+26.6%+25.7%$9.61B$29.05M-19.93860Insider TradeAnalyst RevisionELANElanco Animal Health2.5918 of 5 stars$18.63+0.5%$17.33-6.9%+35.1%$9.21B$4.44B21.669,000News CoverageAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.0039 of 5 stars$106.37-0.1%$109.00+2.5%+258.7%$9.17B$42.28M-107.4430Positive NewsMRNAModerna4.4982 of 5 stars$23.88+1.6%$41.81+75.1%-59.5%$9.15B$3.24B-3.175,800Trending NewsRVMDRevolution Medicines4.2703 of 5 stars$46.20-0.8%$73.67+59.5%-1.9%$8.70B$11.58M-10.27250 Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors QIAGEN Competitors BridgeBio Pharma Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Verona Pharma PLC American Depositary Share Competitors Moderna Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRNX Stock Alerts